Northland Securities Forecasts Strong Price Appreciation for Brainsway (NASDAQ:BWAY) Stock

Key Points

• Northland Securities has increased its price target for Brainsway (NASDAQ:BWAY) from $15.00 to $19.00, indicating a potential upside of 47.23% based on the stock's previous close.
• Brainsway's stock has recently traded at $12.91 and has a market capitalization of $243.90 million, along with a P/E ratio of 64.61.
• The company reported an earnings per share (EPS) of $0.10, surpassing estimates and highlighting a net margin of 9.01% for the quarter.

Brainsway (NASDAQ:BWAY - Get Free Report) had its price target lifted by equities research analysts at Northland Securities from $15.00 to $19.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Northland Securities' price objective indicates a potential upside of 31.31% from the stock's current price.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Brainsway from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Wall Street Zen cut shares of Brainsway from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $18.00.

Brainsway Stock Performance

NASDAQ BWAY traded down $0.38 on Thursday, hitting $14.47. The stock had a trading volume of 87,142 shares, compared to its average volume of 56,977. The firm has a 50-day moving average of $12.21 and a 200-day moving average of $10.59. The company has a market capitalization of $273.48 million, a price-to-earnings ratio of 55.66 and a beta of 1.42. Brainsway has a 52-week low of $7.06 and a 52-week high of $15.00.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. The firm had revenue of $12.63 million for the quarter, compared to analysts' expectations of $12.34 million. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. Brainsway has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Brainsway will post 0.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainsway

A number of hedge funds have recently modified their holdings of BWAY. Lazard Asset Management LLC bought a new position in shares of Brainsway during the fourth quarter worth $44,000. Raymond James Financial Inc. bought a new position in shares of Brainsway during the second quarter worth $85,000. GAMMA Investing LLC lifted its position in Brainsway by 720.7% during the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after purchasing an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Brainsway in the 1st quarter worth $111,000. Finally, Trexquant Investment LP purchased a new position in shares of Brainsway in the 1st quarter worth $129,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.